Lipum AB (publ) (STO:LIPUM)

Market Cap	304.40M -19.4%
Revenue (ttm)	n/a
Net Income	-71.53M
EPS	-3.37
Shares Out	21.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	445,908
Open	14.35
Previous Close	14.25
Day's Range	14.25 - 14.50
52-Week Range	8.56 - 19.95
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2026

About Lipum AB

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LIPUM

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Mar 21, 2026

Data Sources Report a data error